Improving transparency in clinical trial reporting.

IF 15.8 1区医学 Q1 Medicine

PLoS Medicine Pub Date : 2025-04-28 eCollection Date: 2025-04-01 DOI:10.1371/journal.pmed.1004588

Alison Farrell

引用次数: 0

Abstract

The power to interpret the results of randomised clinical trial results relies on transparent reporting of the study design, protocol, methods and analyses. Without such clarity, the benefits of the findings, to both healthcare, policy and research, cannot be realized in full. The publication of the updated CONSORT 2025 and SPIRIT 2025 statements for reporting of randomised clinical trials and protocols, respectively, offers the opportunity to reflect on the power that transparent reporting of clinical trial design and data offers to improve the quality of trials and outcomes.

查看原文本刊更多论文

提高临床试验报告的透明度。

解释随机临床试验结果的能力依赖于研究设计、方案、方法和分析的透明报告。如果没有这样的清晰度，这些发现对医疗保健、政策和研究的好处就无法充分实现。更新后的CONSORT 2025和SPIRIT 2025分别发布了随机临床试验和方案报告声明，这为反思临床试验设计和数据透明报告对提高试验质量和结果的作用提供了机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PLoS Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

17.60

自引率

0.60%

发文量

227

审稿时长

4-8 weeks

期刊介绍： PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings. The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination. PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.